๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hyderabad
Clinical trial register · India

Clinical Trials in Hyderabad

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1125 matching records held by the registry are in this view. Synced 22 Sep 2026, 03:16 UTC
1125
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
221
Lead sponsors
across recruiting studies
Top sites
Kolkata 54 Delhi 40 Bangalore 39 New Delhi 38 Mumbai 37
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Asian Institute of Gastroenterology, India40 AstraZeneca35 Novartis Pharmaceuticals15 Bristol-Myers Squibb15 Eli Lilly and Company14 Clear sponsor filter
Site location
Kolkata54 Delhi40 Bangalore39 New Delhi38 Mumbai37
All 76 locations
Target enrolment
to
35 of 1125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
AstraZeneca
Phase 3
6,950
Belagavi, Calicut, Coimbatore, Dehradun, Delhi, Hyderabad, Jaipur, Kanpur
2026-08-24
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725Obesity or Overweight
AstraZeneca
Phase 3
2,500
Bhubaneswar, Coimbatore, Hyderabad, Indore, Jaipur, Jodhpur, Kochi, Kolkata
2026-08-19
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
NCT07664553Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
600
Bangalore, Belagavi, Chennai, Coimbatore, Guntur, Hyderabad, Indore, Kochi
2026-07-08
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803Weight Management
AstraZeneca
Phase 3
4,500
Bangalore, Belagavi, Bikaner, Delhi, Guntur, Hyderabad, Jaipur, Jodhpur
2026-06-29
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
AstraZeneca
Phase 3
2,130
Ahmedabad, Bhubaneswar, Hyderabad, Kolkata, Mohali, Mumbai, New Delhi, Varanasi
2026-02-03
Recruiting
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
NCT06531798Moderate to Severe COPD
AstraZeneca
Phase 4
150
Dalgate, Drugjan, Hyderabad, Lucknow, Nagpur, New Delhi
2026-01-30
Active, closed
Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease
NCT06851806Respiratory Syncytial Virus (RSV)
AstraZeneca
Not applicable
21
Hyderabad, Jhฤnsi, Kanpur, Kolkata, Mysore, Nagpur, Pune, Vidyanagar, Hubballi
2025-12-10
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
AstraZeneca
Phase 3
1,100
Delhi, Hyderabad, Kolhฤpur, Kolkata, Mumbai, Nashik, Surat
2025-12-04
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
AstraZeneca
Phase 3
250
Belagavi, Delhi, Hyderabad, Kolkata, Mumbai
2025-08-07
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
AstraZeneca
Phase 3
700
Ansฤrinagar, Babgalore, Calicut, Delhi, Hyderabad, Kannur, Kanpur, Mumbai
2025-08-06
Recruiting
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT07082738Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 2
987
Belagavi, Coimbatore, Dehradun, Delhi, Dwฤrka, Hyderabad, Kochi, Mumbai
2025-06-27
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
AstraZeneca
Phase 3
1,220
Ahmedabad, Bangalore, Binnฤguri, Dehradun, Delhi, Hyderabad, Mumbai, Nashik
2025-05-06
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Ahmedabad, Ajmer, Bangalore, Belagavi, Dehradun, Delhi, Gurgaon, Hyderabad
2025-03-14
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
5,000
Bangalore, Belagavi, Hyderabad, Kolkata, Madurai, Mumbai, New Delhi, Pune
2025-03-03
Recruiting
A Phase โ…ข Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 3
840
Ansฤrinagar, Bangalore, Delhi, Hyderabad, Kolkata, Mumbai, Varanasi
2025-03-01
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
744
Amravati, Bhubaneswar, Hyderabad, Kolhฤpur, Mumbai, Mysuru, Namakkal, Pune
2024-10-04
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Ahmedabad, Dehradun, Delhi, Gurugram, Hyderabad, Kolkata, Lucknow, Mumbai
2024-06-20
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
AstraZeneca
Phase 3
582
Bangalore, Delhi, Hyderabad, Kolkata, Mysuru, Nagpur, Nashik, New Delhi
2024-04-29
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
2,554
Bangalore, Belagavi, Calicut, Chennai, Coimbatore, Dehradun, Hyderabad, Kolkata
2024-03-29
Active, closed
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer
AstraZeneca
Phase 3
594
Ahmedabad, Hyderabad, Mumbai, New Delhi
2024-03-04
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 3
1,145
Bengaluru, Hyderabad, Jaipur, Kanpur, Kochi, Kolkata, Lucknow, Madurai
2023-12-14
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Ahmedabad, Delhi, Gurugram, Hyderabad, Kolkata, Mumbai, Mysuru, New Delhi
2023-11-08
Active, closed
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
895
Bengaluru, Hyderabad, Kolkata, Mysuru, Nagpur, Varanasi
2023-10-24
Active, closed
Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.
NCT05817110Lung Malignancy
AstraZeneca
Observational
712
Gurugram, New Delhi, Hyderabad, Bangalore, Chennai, Kolkata, Mumbai, Pune
2023-04-20
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
4,300
Bangalore, Belagavi, Bhubaneswar, Hubli, Hyderabad, Jaipur, Kolkata, Mumbai
2023-03-31
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
AstraZeneca
Phase 3
3,527
Ahmedabad, Belagavi, Chennai, Dehradun, Gurgaon, Gurugram, Hyderabad, Kanpur
2022-12-13
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
AstraZeneca
Phase 3
760
Ahmedabad, Bangalore, Delhi, Hyderabad, Jaipur, Kolkata, Mumbai, New Delhi
2022-03-28
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
791
Ahmedabad, Bangalore, Delhi, Howrah, Hyderabad, Jaipur, Kolkata, Marg Jaipur
2022-02-18
Active, closed
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133Lupus Nephritis
AstraZeneca
Phase 3
363
Ahmedabad, Dehradun, Delhi, Hyderabad, Kolkata, Nadiฤd, Pune, Secunderabad
2022-02-15
Active, closed
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
454
Bangalore, Delhi, Hyderabad, Mumbai, Nashik
2021-10-28
Active, closed
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866Breast Cancer
AstraZeneca
Phase 3
732
Gurgaon, Howrah, Hyderabad, Jaipur, Kolkata, Nashik, Surat, Visakhapatnam
2021-10-18
Active, closed
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03847428Hepatocellular Carcinoma
AstraZeneca
Phase 3
908
Bangalore, Hyderabad, Kolkata, Mumbai, New Delhi
2019-04-29
Active, closed
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03778957Hepatocellular Carcinoma
AstraZeneca
Phase 3
724
Bangalore, Bengaluru, Hyderabad, Kolkata, Madurai, Mumbai, Nashik, Pune
2018-11-30
Active, closed
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03298451Hepatocellular Carcinoma
AstraZeneca
Phase 3
1,324
Bangalore, Bhubneshwar, Chennai, Hubli, Hyderabad, Karmsad, Mumbai, Nashik
2017-10-11
Active, closed
Comparison of Fulvestrant (FASLODEXโ„ข) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
NCT00099437Breast Cancer
AstraZeneca
Phase 3
736
Ansฤrinagar, Bhopal, Hyderabad, Jaipur, Kolkata, Manipal, Marg Jaipur, Mumbai
2005-02-13
Rows per page Showing 1–35 of 35
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-india/city/hyderabad

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.